@Article{Ruprecht2011,
journal="Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review",
issn="1896-9666",
year="2011",
title="Review paperEffects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system",
abstract="Glucagon-like peptide-1 (GLP-1) agonists give the opportunity for multiple clinical intervention in type 2 diabetes patients. Beyond glucose control, use of GLP-1 agonists may cause reduction of cardiovascular risk factors. Experimental studies and clinical trials have shown numerous clinical benefits of GLP-1 and the GLP-1 analogue liraglutide on the cardiovascular system, independent of their glycaemic effect. A more complete view of liraglutide’s cardiovascular effect will be provided based on results from the prospective phase III trial LEADER TM .",
author="Ruprecht, Zofia
and Małecki, Piotr",
pages="220--224",
url="https://www.termedia.pl/-Review-paper-Effects-of-liraglutide-a-GLP-1-receptor-agonist-on-the-cardiovascular-system-,47,17462,1,1.html"
}